Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Looks Ahead To 2011, But Avastin Woes And Other Concerns Could Pose Challenges

This article was originally published in The Pink Sheet Daily

Executive Summary

After several setbacks in 2010, the Swiss Pharma lowers its guidance on its best-selling drug and braces for the results from a key study.

You may also be interested in...



Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year

Regeneron Pharmaceuticals Inc. is hoping to launch aflibercept ophthalmic solution in the fall with clinically equivalent trial results and a dosing advantage over Roche 's VEGF inhibitor Lucentis (ranibizumab), the current standard of care for "wet" age-related macular degeneration.

Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year

Regeneron Pharmaceuticals Inc. is hoping to launch aflibercept ophthalmic solution in the fall with clinically equivalent trial results and a dosing advantage over Roche 's VEGF inhibitor Lucentis (ranibizumab), the current standard of care for "wet" age-related macular degeneration.

Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year

If the ophthalmic product wins priority review, Roche could see competition for Lucentis in wet AMD by the fall.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071858

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel